A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01824875

Title field or adapter rule

{'original_value': 'A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:24.547364+00:00

Published At

2022-10-19T00:00:00+00:00

Record Updated At

2026-09-29

Results Posted At

2022-10-19

Source Retrieved At

2026-10-31T22:17:54.613222+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Gastrinoma", "Glucagonoma", "Insulinoma", "Islet Cell Carcinoma", "Pancreatic Polypeptide Tumor", "Recurrent Islet Cell Carcinoma", "Somatostatinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT01824875"

protocolSection.identificationModule.officialTitle

"A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2022-10-19", "type": "ACTUAL"}

Study condition terms

• Gastrinoma (protocolSection.conditionsModule.conditions)
• Glucagonoma (protocolSection.conditionsModule.conditions)
• Insulinoma (protocolSection.conditionsModule.conditions)
• Islet Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Pancreatic Polypeptide Tumor (protocolSection.conditionsModule.conditions)
• Recurrent Islet Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Somatostatinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm A (temozolomide)', 'Arm B (temozolomide and capecitabine)'], 'description': 'Given PO', 'name': 'temozolomide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm B (temozolomide and capecitabine)'], 'description': 'Given PO', 'name': 'capecitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• temozolomide (protocolSection.armsInterventionsModule.interventions[].name)
• capecitabine (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.